Gentlemen, no need to get at each others' throats! SRX has a stong lead product which has achieved 2% market penetration in USA. It stands to double the survival of those with colon cancer in the liver and as further data is produced from US trials, which are ongoing, then market penetration will continue to build. SRX is looking at doubling sales in US this coming year and when units sales double for any company in any industry, the sp goes up. SRX has strong management team who have taken very few/no wrong steps. They have a stong team in US and as it builds, so will the company's capacity to deliver scalable growth. My DCF valuation suggests a 12 month sp range of $5-5.5. Main contra factors are that stock is tightly held and many analysts have turned their backs on SRX ever since Cephalon deal did not proceed. CPH have been speaking with SRX and are evaluating making an investment as they have done with BZI, which also has very strong (ex-GE Healthcare) management.
- Forums
- ASX - By Stock
- srx
Gentlemen, no need to get at each others' throats! SRX has a...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.91M |
Open | High | Low | Value | Volume |
16.0¢ | 16.0¢ | 16.0¢ | $730.9K | 4.568M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 1667096 | 15.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.5¢ | 264086 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1667096 | 0.155 |
10 | 2627800 | 0.150 |
3 | 591379 | 0.145 |
1 | 60000 | 0.140 |
1 | 153846 | 0.130 |
Price($) | Vol. | No. |
---|---|---|
0.165 | 211086 | 7 |
0.170 | 99369 | 3 |
0.175 | 181000 | 2 |
0.180 | 30000 | 1 |
0.185 | 3000 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |